Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy

Intravenous silibinin (ivSIL) is a potent antiviral agent against HCV. In vitro silibinin (SIL) inhibits viral replication, possibly by inhibiting HCV RNA polymerase. In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (s...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral therapy 2011-01, Vol.16 (8), p.1327-1333
Main Authors: RUTTER, Karoline, SCHERZER, Thomas-Matthias, BEINHARDT, Sandra, KERSCHNER, Heidrun, STÄTTERMAYER, Albert F, HOFER, Harald, POPOW-KRAUPP, Theresia, STEINDL-MUNDA, Petra, FERENCI, Peter
Format: Article
Language:English
Subjects:
Adult
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antioxidants - administration & dosage
Antioxidants - therapeutic use
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Austria
Biological and medical sciences
Cohort Studies
Drug Therapy, Combination - methods
Female
Hepacivirus - drug effects
Hepacivirus - physiology
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Humans
Injections, Intravenous
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Interferons
Interleukins - genetics
Interleukins - immunology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Recurrence
Ribavirin - administration & dosage
Ribavirin - therapeutic use
RNA, Viral - analysis
Silybin
Silymarin - administration & dosage
Silymarin - therapeutic use
Treatment Outcome
Viral Load - drug effects
Virus Replication - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravenous silibinin (ivSIL) is a potent antiviral agent against HCV. In vitro silibinin (SIL) inhibits viral replication, possibly by inhibiting HCV RNA polymerase. In this proof-of-concept study, ivSIL was tested in on-treatment non-responders to full-dose of pegylated interferon-α2a/ribavirin (standard of care [SOC]). A total of 27 treatment-naive patients with
ISSN:1359-6535
2040-2058
DOI:10.3851/IMP1942